Mouse anti Dog CD8 beta antibody, clone CA15.4G2 recognises the canine CD8β cell surface antigen, expressed by cytotoxic\suppressor T lymphocytes that interact with MHC Class I expressing targets.
- Target Species
- Product Form
- Tissue Culture Supernatant - liquid
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 18 months from date of despatch.
- For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of CD8 Beta antibody
|Immunohistology - Frozen 1
|Immunohistology - Paraffin
- 1The epitope recognised by this antibody is reported to be sensitive to formaldehyde fixation and tissue processing. Bio-Rad recommends the use of acetone fixation for frozen sections.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 20ul of the suggested working dilution to label 106 cells or 100ul whole blood.
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Negative Isotype Controls Available
Application Based External Images
Product Specific References
References for CD8 Beta antibody
Luckschander, N. et al. (2009) Phenotyping, functional characterization, and developmental changes in canine intestinal intraepithelial lymphocytes.
Vet Res. 40: 58.
Pumarola, M. et al. (2004) Canine inflammatory myopathy: analysis of cellular infiltrates.
Muscle Nerve. 29: 782-9.
Vernau, W. and Moore, P.F. (1999) An immunophenotypic study of canine leukemias and preliminary assessment of clonality by polymerase chain reaction.
Vet Immunol Immunopathol. 69: 145-64.
Moreno, J. et al. (1999) The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy.
Vet Immunol Immunopathol. 71: 181-95.
Kisseberth, W.C. et al. (2007) A novel canine lymphoma cell line: a translational and comparative model for lymphoma research.
Leuk Res. 31: 1709-20.
Gauthier, M.J. et al. (2005) The immunophenotype of peripheral blood lymphocytes in clinically healthy dogs and dogs with lymphoma in remission.
J Vet Intern Med. 19: 193-9.
Sonea, I.M. et al. (2000) Flow cytometric analysis of colonic and small intestinal mucosal lymphocytes obtained by endoscopic biopsy in the healthy dog.
Vet Immunol Immunopathol. 77: 103-19.
Lau, K.W. et al. (1999) Large granular lymphocytic leukemia in a mixed breed dog.
Can Vet J. 40: 725-8.
Wilkerson, M.J. et al. (2005) Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules.
Vet Immunol Immunopathol. 106: 179-96.
Izci C et al. (2015) Clinical and light microscopic studies of the conjunctival tissues of dogs with bilateral keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine.
Biotech Histochem. 90 (3): 223-30.
Moore, P.F. et al. (1992) Monoclonal antibodies specific for canine CD4 and CD8 define functional T lymphocyte subsets and high density expression of CD4 by canine neutrophils.
Tissue Antigens 40: 75-85.